Ambra Health Launches Next-Generation ProViewer
Diagnostic viewer is designed to give providers personalized anywhere, anytime access to medical imaging.
Ambra Health has released Ambra ProViewer, its next generation cloud-based diagnostic viewer that is designed to give providers anywhere, anytime access to images.
By pairing its U.S. Food & Drug Administration-cleared ProViewer with a cloud PACS system, this tool is designed to give providers personalized mobile access to manage diagnostic images and supplemental photos and videos. It also offers full diagnostic, read-at-home, and teleradiology capabilities.
Courtesy: Ambra Health
According to a company statement, the ProViewer offers three key features:
- Easy Deployment, High Customization: A customizable keyboard and intuitive interface allows providers to choose exactly how they want to view images. It can be either a diagnostic reader or a universal viewer.
- Advanced Toolset: Multi-planar reconstruction, surface and volume rendering, and anatomical re-ordering can help providers in various areas, including research, orthopedics, and oncology.
- All-Access: All major web browsers support ProViewer without the need for any downloads, and it works on both iOS and Android mobile devices.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Assesses Potential of Seven-Minute AI-Enhanced 3T MRI of the Shoulder
February 20th 2025Researchers found that the use of seven-minute threefold parallel imaging-accelerated deep learning 3T MRI had 89 percent sensitivity for supraspinatus-infraspinatus tendon tears and 93 percent sensitivity for superior labral tears.
Study Explores Impact of Insurance on Treatment and Referrals for Patients with Uterine Fibroids
February 19th 2025Women with uterine fibroids and Medicaid coverage are significantly more likely to be treated with uterine artery embolization than those with commercial insurance, according to newly published research.
